Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Bad Krozingen – page 35

689 clinical trials in Bad Krozingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Krozingen at a glance
689
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

689 trials in Bad Krozingen

Open in trial search

Breast cancer

Not recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Cardiac amyloidosis

Not recruiting

Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:AstraZeneca AB

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Systemic sclerosis pulmonary

Not recruiting

Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Prometheus Biosciences Inc.

Choroidal neovascularisation

Not recruiting

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.

Small cell lung cancer

Not recruiting

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Serplulimab
  • Sponsor:Shanghai Henlius Biotech Inc.

Type 2 diabetes mellitus

Not recruiting

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Dermatomyositis

Not recruiting

A study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Priovant Therapeutics Inc.

Arteriosclerosis+1

Not recruiting

A study testing DII235 compared to placebo in adults with high lipoprotein(a) levels to reduce heart disease risk

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:DII235
  • Sponsor:Novartis Pharma AG

Malignant melanoma stage IV+1

Not recruiting

Study of BNT111 and cemiplimab in patients with advanced melanoma who have not responded to other therapies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:BioNTech SE

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Bad Krozingen

What the registry says about research in the country

01 Cardiovascular Disease Management

Innovative research focusing on lipoprotein management and preventive therapies for cardiovascular disease, exploring new treatments to reduce major cardiovascular events in high-risk patients.

  • Cardiovascular death prevention
  • Stroke prevention
  • Myocardial infarction management

Advanced studies evaluating novel therapeutic approaches for better cardiovascular outcomes.

02 Thrombosis and Embolism

Clinical investigations into deep vein thrombosis treatments and prevention of systemic embolism, particularly in patients with atrial fibrillation.

  • Clot lysis therapy
  • Pulmonary embolism treatment
  • Anticoagulation strategies

Comprehensive research on blood clot prevention and treatment methodologies.

03 Cardiac Conditions

Studies addressing hypertension management and innovative treatments for acute coronary syndromes, including specialized interventions for heart attack prevention.

  • Blood pressure control
  • Acute myocardial infarction
  • Coronary interventions

Evaluating cutting-edge therapies for various cardiac conditions.

04 Vascular Health

Research focusing on peripheral arterial disease and advanced vascular interventions, including novel contrast medium strategies for better patient outcomes.

  • Peripheral vascular interventions
  • Kidney protection strategies
  • Vascular disease management

Developing safer and more effective vascular treatment approaches.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.